GlassScriptPhysician profile
Evan Jacob Levy
NPI 1821529181
$3,478.63
in general payments reported to CMS, 2019-2025
38 companies · $2,830 in 2025
The $2,830 reported for 2025 was more than what 82% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $9.56 · 2024: $639 · 2025: $2,830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,478.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $533.50 | 2025 | Perclot, Tisseel |
| Glaxosmithkline, LLC. | $324.71 | 2024-2025 | Jemperli, Zejula |
| Abbvie INC. | $261.68 | 2025 | |
| Janssen Biotech, INC. | $236.48 | 2024-2025 | Carvykti, Talvey, Rybrevant |
| Lsi Solutions INC | $200.05 | 2024-2025 | Fornisee |
| Pfizer INC. | $181.09 | 2024-2025 | |
| Intuitive Surgical, INC. | $171.24 | 2023-2025 | |
| Davol INC. | $148.32 | 2025 | Arista |
| Bayer Healthcare Pharmaceuticals INC. | $147.74 | 2025 | |
| Merck Sharp & Dohme LLC | $100.07 | 2024-2025 | Keytruda, Welireg, Reblozyl |
| Genentech USA, INC. | $90.44 | 2025 | Phesgo, Polivy |
| Tempus Ai, INC | $87.84 | 2024 | Xt Cdx |
| Novartis Pharmaceuticals Corporation | $84.27 | 2024-2025 | |
| Radiometer America, INC | $80.59 | 2024 | |
| Eisai INC. | $78.35 | 2024-2025 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.